Silexion Therapeutics Corp - Ordinary Shares (SLXN)
SLXN moved a median of -1.33% 30 minutes after news, and -0.70% by the close. How SLXN actually reacts to news — the realized, point-in-time move the market made, measured across 157 labeled events over the last three years with zero look-ahead.
SLXN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.68% | 31% | 150 |
| 30-min | -1.33% | 34% | 156 |
| 60-min | -1.88% | 33% | 156 |
| to close | -0.70% | 45% | 154 |
| Middle 50% of SLXN reactions | -4.04% to +1.37% |
|---|---|
| Median reaction (30-min) | -1.33% |
| Measured reactions | 157 |
Half of all Silexion Therapeutics Corp - Ordinary Shares news events land between -4.04% and +1.37% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when SLXN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SLXN's baseline. Nothing else.
Recent SLXN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form DEFA14A Silexion Therapeutics | SEC filing · Form DEFA14A | SEC EDGAR | +2.81% | +0.52% | |
| Form DEF 14A Silexion Therapeutics For: Oct 05 | SEC filing · Form DEF | SEC EDGAR | -3.80% | -2.16% | |
| Form 8-K Silexion Therapeutics For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | -3.09% | +3.28% | |
| Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer | Press release | GlobeNewswire | -3.09% | +3.28% | |
| Form 8-K Silexion Therapeutics For: Sep 28 | SEC filing · Form 8-K | SEC EDGAR | -0.16% | +1.69% | |
| Silexion Therapeutics Announces Exercise of Warrants | Press release | GlobeNewswire | -4.91% | -0.53% | |
| Form 8-K Silexion Therapeutics For: Sep 28 | SEC filing · Form 8-K | SEC EDGAR | -1.03% | -5.26% | |
| Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers | Press release | GlobeNewswire | -1.03% | -5.26% | |
| Form 8-K Silexion Therapeutics For: Sep 25 | SEC filing · Form 8-K | SEC EDGAR | -1.03% | -5.26% | |
| Form PRE 14A Silexion Therapeutics For: Sep 25 | SEC filing · Form PRE | SEC EDGAR | -1.03% | -5.26% | |
| Form DEFA14A Silexion Therapeutics | SEC filing · Form DEFA14A | SEC EDGAR | +0.03% | +3.83% | |
| Form DEFA14A Silexion Therapeutics | SEC filing · Form DEFA14A | SEC EDGAR | -1.37% | +1.76% | |
| Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences | Press release | GlobeNewswire | -1.68% | +1.33% | |
| Form DEF 14A Silexion Therapeutics For: Aug 24 | SEC filing · Form DEF | SEC EDGAR | +0.44% | +1.36% | |
| Form 8-K Silexion Therapeutics For: Aug 21 | SEC filing · Form 8-K | SEC EDGAR | -1.75% | -2.49% | |
| Form 10-Q Silexion Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.43% | +0.29% | |
| Form 8-K Silexion Therapeutics For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -0.43% | +0.29% | |
| Form PRE 14A Silexion Therapeutics For: Aug 14 | SEC filing · Form PRE | SEC EDGAR | -1.84% | +2.18% | |
| Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.43% | +0.29% | |
| Form 8-K Silexion Therapeutics For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -0.43% | +0.29% | |
| Form EFFECT Silexion Therapeutics | SEC filing · Form EFFECT | SEC EDGAR | +5.31% | +3.51% | |
| Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering | Press release | GlobeNewswire | +5.31% | +3.51% | |
| Form 8-K Silexion Therapeutics For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form S-1/A Silexion Therapeutics | SEC filing · Form S-1 | SEC EDGAR | -10.74% | -30.54% | |
| Form S-1 Silexion Therapeutics | SEC filing · Form S-1 | SEC EDGAR | -3.31% | — | |
| Form 8-K Silexion Therapeutics For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | -3.33% | -7.69% | |
| Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers | Press release | GlobeNewswire | -1.75% | +11.11% | |
| Form 8-K Silexion Therapeutics For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | -1.57% | +2.09% | |
| Form 8-K Silexion Therapeutics For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | -1.57% | +2.09% | |
| Form 8-K Silexion Therapeutics For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | -0.63% | +15.00% | |
| Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center | Press release | GlobeNewswire | -0.02% | -22.70% | |
| Form 8-K Silexion Therapeutics For: Jul 21 | SEC filing · Form 8-K | SEC EDGAR | +0.39% | -1.56% | |
| Form DEFA14A Silexion Therapeutics | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -3.10% | |
| Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer | Press release | GlobeNewswire | -1.14% | +2.65% | |
| Form EFFECT Silexion Therapeutics | SEC filing · Form EFFECT | SEC EDGAR | -1.27% | -1.64% | |
| Form DEF 14A Silexion Therapeutics For: Jun 16 | SEC filing · Form DEF | SEC EDGAR | -4.49% | +8.61% | |
| Silexion Therapeutics to Attend BIO International Convention 2026 | Press release | GlobeNewswire | -4.49% | +8.61% | |
| Form S-3 Silexion Therapeutics | SEC filing · Form S-3 | SEC EDGAR | -3.43% | -14.33% | |
| Form PRE 14A Silexion Therapeutics For: Jun 03 | SEC filing · Form PRE | SEC EDGAR | -2.94% | +4.20% | |
| Form 8-K Silexion Therapeutics For: May 29 | SEC filing · Form 8-K | SEC EDGAR | +1.86% | +18.87% | |
| Form S-8 Silexion Therapeutics | SEC filing · Form S-8 | SEC EDGAR | +1.86% | +18.87% | |
| Form 8-K Silexion Therapeutics For: May 26 | SEC filing · Form 8-K | SEC EDGAR | -1.74% | +2.21% | |
| Silexion Therapeutics Announces 1-for-10 Reverse Share Split | Press release | GlobeNewswire | -1.74% | +2.21% | |
| Form 10-K/A Silexion Therapeutics For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.21% | -12.57% | |
| Form 8-K Silexion Therapeutics For: May 18 | SEC filing · Form 8-K | SEC EDGAR | -1.44% | -3.77% | |
| Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -1.44% | -3.77% | |
| Form 10-Q Silexion Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.44% | -3.77% | |
| Form 8-K Silexion Therapeutics For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -1.44% | -3.77% | |
| Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds | Press release | GlobeNewswire | -10.62% | -0.34% | |
| Form 8-K Silexion Therapeutics For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -10.62% | -0.34% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SLXN section they belong to.
Where else SLXN is measured.
SLXN earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Silexion Therapeutics Corp - Ordinary Shares's median reaction calculated?
Every labeled SLXN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 157 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 34% of SLXN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SLXN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.